It’s reassuring to know the good folk at the US Food & Drug Administration (FDA) are still on the tools, despite the upheaval ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Thanks to a loophole in the Federal Food, Drug, and Cosmetic Act of 1938, some of the “drugs” you can buy at pharmacies are ...

Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...

Tesla boss Elon Musk seems to be on a mission to conquer the world, and even Mars. But his odd-hour rants, alleged Nazi ...

Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...

The company has committed to refraining from additional draws on the ELOC for either 30 trading days or until its share price reaches $10, demonstrating confidence in its near-term business prospects.

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

Net research and development expenses for the device division increased in 2024 to CAD175,000 from CAD44,000 in 2023, a 400% increase. The increase is attributed to development of a new software ...